Immuneering (IMRX) Assets Average (2021 - 2026)

Immuneering's Assets Average history runs 6 years deep, the most recent figure standing at $223.4 million for Q1 2026.

• On a quarterly basis, Assets Average rose 332.12% year-over-year to $223.4 million in Q1 2026; TTM through Mar 2026 was $223.4 million, a 332.12% increase from a year earlier, with the FY2025 full-year figure at $142.3 million, up 83.32% from the prior year.
• Assets Average retreated to $223.4 million in Q1 2026 per IMRX's latest filing, from $236.5 million in the prior quarter.
• Across five years, Assets Average topped out at $236.5 million in Q4 2025 and bottomed at $45.4 million in Q2 2025.
• The 5-year median for Assets Average is $116.3 million (2023), against an average of $120.0 million.
• Across the five-year window, Assets Average tumbled 45.74% in 2025 and jumped 332.12% in 2026, its largest moves.
• Year by year, Assets Average stood at $128.0 million in 2022, then dropped by 15.46% to $108.2 million in 2023, then slumped by 43.98% to $60.6 million in 2024, then soared by 290.07% to $236.5 million in 2025, then dropped by 5.55% to $223.4 million in 2026.
• Per Business Quant, the three latest IMRX Assets Average figures stand at $223.4 million (Q1 2026), $236.5 million (Q4 2025), and $140.6 million (Q3 2025).